Trial · NCT00225147
Adverse events68
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 68
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | back pain | Musculoskeletal and connective tissue disorders | 100 IU/kg rhC1INH | 0 | 13 | 0 |
| other | back pain | Musculoskeletal and connective tissue disorders | 50 IU/kg rhC1INH | 1 | 12 | 1 |
| other | back pain | Musculoskeletal and connective tissue disorders | Placebo | 0 | 13 | 0 |
| other | back pain | Musculoskeletal and connective tissue disorders | 50 IU/kg Open-label rhC1INH | 0 | 62 | 0 |
| other | headache | Nervous system disorders | 100 IU/kg rhC1INH | 2 | 13 | 2 |
| other | headache | Nervous system disorders | 50 IU/kg rhC1INH | 0 | 12 | 0 |
| other | headache | Nervous system disorders | Placebo | 0 | 13 | 0 |
| other | headache | Nervous system disorders | 50 IU/kg Open-label rhC1INH | 12 | 62 | 23 |
| other | injection site swelling | General disorders | 100 IU/kg rhC1INH | 0 | 13 | 0 |
| other | injection site swelling | General disorders | 50 IU/kg rhC1INH | 0 | 12 | 0 |
| other | injection site swelling | General disorders | Placebo | 1 | 13 | 1 |
| other | injection site swelling | General disorders | 50 IU/kg Open-label rhC1INH | 0 | 62 | 0 |
| other | myalgia | Musculoskeletal and connective tissue disorders | 100 IU/kg rhC1INH | 0 | 13 | 0 |
| other | myalgia | Musculoskeletal and connective tissue disorders | 50 IU/kg rhC1INH | 0 | 12 | 0 |
| other | myalgia | Musculoskeletal and connective tissue disorders | Placebo | 1 | 13 | 1 |
| other | myalgia | Musculoskeletal and connective tissue disorders | 50 IU/kg Open-label rhC1INH | 0 | 62 | 0 |
| other | rash erythematous | Skin and subcutaneous tissue disorders | 100 IU/kg rhC1INH | 0 | 13 | 0 |
| other | rash erythematous | Skin and subcutaneous tissue disorders | 50 IU/kg rhC1INH | 0 | 12 | 0 |
| other | rash erythematous | Skin and subcutaneous tissue disorders | Placebo | 1 | 13 | 1 |
| other | rash erythematous | Skin and subcutaneous tissue disorders | 50 IU/kg Open-label rhC1INH | 0 | 62 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00225147/events